DNA Topoisomerases, Type I
"DNA Topoisomerases, Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix.
| Descriptor ID |
D004264
|
| MeSH Number(s) |
D08.811.399.403.483 D12.776.157.687.375 D12.776.660.720.375
|
| Concept/Terms |
DNA Topoisomerases, Type I- DNA Topoisomerases, Type I
- DNA Nicking-Closing Proteins
- DNA Relaxing Enzyme
- DNA Relaxing Enzymes
- DNA Relaxing Protein
- DNA Topoisomerase
- DNA Topoisomerase I
- DNA Type 1 Topoisomerase
- DNA Untwisting Enzyme
- DNA Untwisting Enzymes
- DNA Untwisting Protein
- DNA Untwisting Proteins
- Topoisomerase I
- Type I DNA Topoisomerase
- DNA Nicking-Closing Protein
|
Below are MeSH descriptors whose meaning is more general than "DNA Topoisomerases, Type I".
Below are MeSH descriptors whose meaning is more specific than "DNA Topoisomerases, Type I".
This graph shows the total number of publications written about "DNA Topoisomerases, Type I" by people in this website by year, and whether "DNA Topoisomerases, Type I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2017 | 1 | 5 | 6 |
| 2018 | 3 | 3 | 6 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "DNA Topoisomerases, Type I" by people in Profiles.
-
TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell. 2021 05 13; 184(10):2618-2632.e17.
-
Topoisomerase III-ß is required for efficient replication of positive-sense RNA viruses. Antiviral Res. 2020 10; 182:104874.
-
[Cancers in systemic sclerosis : risk factors, impact on survival and literature review]. Rev Med Interne. 2019 Oct; 40(10):637-644.
-
Arthritis Mutilans in Systemic Sclerosis. Arthritis Rheumatol. 2019 01; 71(1):120.
-
Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. Clin Exp Rheumatol. 2018 Jul-Aug; 36 Suppl 113(4):68-75.
-
Investigating mycobacterial topoisomerase I mechanism from the analysis of metal and DNA substrate interactions at the active site. Nucleic Acids Res. 2018 08 21; 46(14):7296-7308.
-
Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo. Eur J Pharm Sci. 2018 Oct 15; 123:546-559.
-
DNA Topoisomerase I differentially modulates R-loops across the human genome. Genome Biol. 2018 07 30; 19(1):100.
-
Detection of the Malaria causing Plasmodium Parasite in Saliva from Infected Patients using Topoisomerase I Activity as a Biomarker. Sci Rep. 2018 03 07; 8(1):4122.
-
Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):98-105.